2026-07-06T11:33:55Zhttps://docta.ucm.es/rest/oai/requestoai:docta.ucm.es:20.500.14352/721542025-02-13T16:49:43Zcom_20.500.14352_14col_20.500.14352_15
Martínez Cuadrón, David
Serrano, Josefina
Mariz, José
Gil, Cristina
Tormo, Mar
Martínez Sánchez, María Del Pilar
Rodríguez Arbolí, Eduardo
García Boyero, Raimundo
Rodríguez Medina, Carlos
Martínez Chamorro, Carmen
Polo, Marta
Bergua, Juan
Aguiar, Eliana
Amigo, María
Herrera, Pilar
Alonso Domínguez, Juan Manuel
Bernal, Teresa
Espadana, Ana
Sayas, María
Algarra, Lorenzo
Vidriales, María B.
Vasconcelos, Graça
Vives, Susana
Pérez Encinas, Manuel
López, Aurelio
Noriega Concepción, Víctor
García Fortes, María
Chillón, María
Rodríguez Gutiérrez, Juan
Calasanz, María
Labrador, Jorge
López, Juan
Boluda, Blanca
Rodríguez Veiga, Rebeca
Martínez López, Joaquín
Barragán, Eva
Sanz, Miguel
Montesinos, Pau
2023-06-22T11:09:04Z
2023-06-22T11:09:04Z
2022
2072-6694
10.3390/cancers14112817
https://hdl.handle.net/20.500.14352/72154
https://doi.org/10.3390/cancers14112817
https://www.mdpi.com/2072-6694/14/11/2817
This retrospective study investigated outcomes of 404 patients with relapsed/refractory (R/R) FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) acute myeloid leukemia (AML) enrolled in the PETHEMA registry, pre-approval of tyrosine kinase inhibitors. Most patients (63%) had received first-line intensive therapy with 3 + 7. Subsequently, patients received salvage with intensive therapy (n = 261), non-intensive therapy (n = 63) or supportive care only (n = 80). Active salvage therapy (i.e., intensive or non-intensive therapy) resulted in a complete remission (CR) or CR without hematological recovery (CRi) rate of 42%. More patients achieved a CR/CRi with intensive (48%) compared with non-intensive (19%) salvage therapy (p < 0.001). In the overall population, median overall survival (OS) was 5.5 months; 1- and 5-year OS rates were 25% and 7%. OS was significantly (p < 0.001) prolonged with intensive or non-intensive salvage therapy compared with supportive therapy, and in those achieving CR/CRi versus no responders. Of 280 evaluable patients, 61 (22%) had an allogeneic stem-cell transplant after they had achieved CR/CRi. In conclusion, in this large cohort study, salvage treatment approaches for patients with FLT3-ITD mutated R/R AML were heterogeneous. Median OS was poor with both non-intensive and intensive salvage therapy, with best long-term outcomes obtained in patients who achieved CR/CRi and subsequently underwent allogeneic stem-cell transplant.
eng
https://creativecommons.org/licenses/by/3.0/es/
open access
Atribución 3.0 España
Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia
journal article